Target Modulation by a Kinase Inhibitor Engineered to Induce a Tandem Blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: The Concept of Type III Combi-Targeting

Advances in the development of hybrid anticancer drugs

(2013) Sébastien Fortin et al.   Expert Opinion on Drug Discovery

Biological Effects of AL622, a Molecule Rationally Designed to Release an EGFR and a c-Src Kinase Inhibitor

(2012) Anne-Laure Larroque-Lombard et al.   Chemical Biology & Drug Design

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Species Difference of Esterase Expression and Hydrolase Activity in Plasma

(2012) Fatma Goksin Bahar et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

(2012) Arvin C. Dar et al.   NATURE

Polypharmacology: drug discovery for the future

(2012) A Srinivas Reddy et al.   Expert Review of Clinical Pharmacology

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines

(2011) H Li et al.   Advances in Medical Sciences

Src: a potential target for the treatment of triple-negative breast cancer

(2011) D. Tryfonopoulos et al.   ANNALS OF ONCOLOGY

Synthesis and Studies on Three-Compartment Flavone-Containing Combi-Molecules Designed to Target EGFR, DNA, and MEK

(2011) Anne-Laure Larroque-Lombard et al.   Chemical Biology & Drug Design

Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents

(2011) Carina Neto et al.   NUCLEAR MEDICINE AND BIOLOGY

The combi-targeting concept: Mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle

(2010) Ranjita Banerjee et al.   CELLULAR SIGNALLING

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis and Uptake of Fluorescence-Labeled Combi-molecules by P-Glycoprotein-Proficient and -Deficient Uterine Sarcoma Cells MES-SA and MES-SA/DX5

(2010) Anne-Laure Larroque-Lombard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species

(2010) Margarita I. Todorova et al.   MOLECULAR CANCER THERAPEUTICS

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling

(2009) Jyoti Nautiyal et al.   CANCER LETTERS

Rational Design of Multitargeted Tyrosine Kinase Inhibitors: A Novel Approach

(2009) Sylvie Barchéchath et al.   Chemical Biology & Drug Design

Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc#

(2009) Matthäus Getlik et al.   JOURNAL OF MEDICINAL CHEMISTRY

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Synthesis of Water Soluble Bis-triazenoquinazolines: An Unusual Predicted Mode of Binding to the Epidermal Growth Factor Receptor Tyrosine Kinase

(2008) Anne-Laure Larroque et al.   Chemical Biology & Drug Design

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

(2008) P. Koppikar et al.   CLINICAL CANCER RESEARCH

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Do molecularly targeted agents in oncology have reduced attrition rates?

(2008) Ian Walker et al.   NATURE REVIEWS DRUG DISCOVERY